v3.19.3
Note 11 - Stock Options - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Weighted Average Exercise Price, outstanding (in dollars per share) $ 2.76 $ 0.10 $ 0.10  
Number of Options, outstanding (in shares) 690 19,222,000 19,222,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period (17)      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price $ 93.48      
Number of Options, outstanding (in shares) 731 690 19,222,000 19,222,000
Weighted Average Exercise Price, outstanding (in dollars per share) $ 23.38 $ 2.76 $ 0.10 $ 0.10
Weighted Average Remaining Life in Years, outstanding (Year) 6 years 1 month 6 days 7 years 4 months 24 days 8 years 4 months 24 days 9 years 4 months 24 days
Intrinsic Value, outstanding $ 33 $ 6,956 [1] $ 6,639 [1]  
Options Outstanding, Vested and expected to vest (in shares)   19,222,000    
Weighted Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)   $ 0.10    
Weighted-average Remaining Contractual Life, Vested and expected to vest (Year)   7 years 4 months 24 days    
Aggregate Intrinsic Value, Vested and expected to vest [1]   $ 6,956    
Number of Options, exercisable (in shares) 550 11,146,000    
Weighted Average Exercise Price, exercisable (in dollars per share) $ 30.07 $ 0.09    
Weighted Average Remaining Life in Years, exercisable (Year) 5 years 9 months 18 days 7 years 4 months 24 days    
Intrinsic Value, exercisable $ 33 $ 4,119 [1]    
Shares Available For Grant, Balance (in shares)   5,000 5,000 5,000
Alliqua Biomedical, Inc. [Member]        
Number of Options, outstanding (in shares) 58      
Weighted Average Exercise Price, outstanding (in dollars per share) $ 289.76      
[1] The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company’s common stock of $0.46 and $0.44 per share as of December 31, 2018 and 2017.